Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
132 USD | +0.15% | +6.74% | +21.03% |
Mar. 28 | Robert Davis, Merck CEO: Another obesity drug? | MT |
Mar. 28 | Merck: new indication approved for Keytruda in Europe | CF |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock
- Equities
- Stock Merck & Co., Inc. - Nyse
- Revisions Merck & Co., Inc.